Evista is the market name of the drug raloxifene HCl is manufactured by drug maker Eli Lilly & Co. a study was conducted which showed that Evista , a drug used to treat osteoporosis in women, did not prevent heart attacks. The study analyzed 10,000 women in 26 countries for a period of seven years. It was studied whether if this drug given daily for the study period would lower the risks of heart attack and breast cancer in postmenopausal women who either had heart disease or were at high risk for heart attack.
Raloxifene HCl is mainly used to treat and prevent osteoporosis in postmenopausal women. But since this study proved that the drug did not prevent heart attacks the company wanted to reinforce for physicians that Evista should not be prescribed for cardioprotection. Lilly Chief Medical Officer Alan Breier said in a statement that they have gathered new data on Evista's potential to reduce the risk of invasive breast cancer in postmenopausal women. It plans to submit the details of its study to the Food and Drug Administration for review. But further analysis would be needed and precautionary measures to be taken before announcing the use of the drug with respect to breast cancer.
